Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Exagen Inc. (Nasdaq: XGN), a prominent player in the autoimmune diagnostics sector, has announced its participation in two significant investor conferences in November 2025. The events include the 16th Annual Craig-Hallum Alpha Select Conference on November 18 at the Sheraton New York Times Square Hotel and the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20 at the Westin NY Grand Central.

Headquartered in Carlsbad, California, Exagen is focused on improving the lives of patients dealing with chronic autoimmune diseases through advanced testing solutions. The company's mission revolves around providing clarity in decision-making related to autoimmune disorders, ultimately enhancing clinical outcomes. One of its hallmark offerings, the AVISE® CTD test, plays a crucial role in diagnosing intricate autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease with greater accuracy and earlier in the disease process.

Exagen operates a CLIA-certified and CAP-accredited laboratory that specializes in rheumatic disease testing, ensuring it delivers timely and precise results for clinicians. Its comprehensive suite of AVISE-branded tests aids in the diagnosis, prognosis, and monitoring of autoimmune diseases, showcasing Exagen's commitment to addressing the multifaceted challenges in autoimmune disease management.

Through a strong foundation in research, innovation, and patient-centered care, Exagen aims to remain at the forefront of autoimmune diagnostics. For more information about the company, including its offerings and initiatives, interested parties can visit Exagen's website or follow them on LinkedIn. As Exagen prepares to engage with investors, it is positioned to highlight its advancements and contributions to the field of autoimmune health care.

As Exagen Inc. (NASDAQ: XGN) prepares to showcase its capabilities at the upcoming 16th Annual Craig-Hallum Alpha Select Conference on November 18 and the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on November 20, it presents a compelling opportunity for investors. The company's strong focus on autoimmune diagnostics, particularly its flagship AVISE® CTD product, catalyzes interest given the growing need for precise and timely diagnosis in chronic autoimmune conditions like lupus and rheumatoid arthritis.

On a fundamental level, Exagen's dedication to research and innovation positions it well in a market that is increasingly emphasizing precision medicine. The increasing prevalence of autoimmune diseases has led to substantial demand for advanced diagnostic solutions, making Exagen's clinical offerings strategically important. The company's CLIA-certified and CAP-accredited laboratory ensures high standards of quality, which enhances its reliability in the eyes of healthcare providers and patients alike.

Investors should consider that participation in high-profile conferences also serves as a marketing tool, allowing Exagen to potentially attract new partnerships, collaborations, or even customers. This exposure could translate into an uptick in sales and an expanding market share, particularly in a sector that is evolving rapidly.

While market trends indicate a positive growth trajectory for diagnostics, potential investors should remain aware of broader market conditions that may impact healthcare funding, regulatory changes, and competition from emerging players. Assessing Exagen's historical performance metrics and engaging with the insights provided during these conferences can yield valuable information.

In summary, Exagen offers a unique investment opportunity driven by its innovative product line and strategic positioning within the autoimmune diagnostics space. Investors should monitor developments from the upcoming conferences, keeping an eye on the company’s growth narrative as it continues to evolve.